J. Wouter Jukema, MD, PhD, FESC, FACC MC

J. Wouter Jukema, MD, PhD, FESC, FACC MC

Professor of Cardiology

Netherlands Heart Foundation

Chairman, Leiden Vascular Medicine

Leiden University Medical Center (LUMC)

Leiden, Netherlands

Related Videos

Since both PCSK9 outcome trials demonstrated impressive safety when LDL-C levels are lowered into ranges much lower than 70 mg/dL, what should be the approach of the interventional and medical cardiologist to achieving LDL-C levels in this range? Video

Since both PCSK9 outcome trials demonstrated impressive safety when LDL-C levels are lowered into ranges much lower than 70 mg/dL, what should be the approach of the interventional and medical cardiologist to achieving LDL-C levels in this range?

What has been your experience with respect to patient satisfaction, discontinuation rates and toleration of this injection-based approach to LDL-C management? Video

What has been your experience with respect to patient satisfaction, discontinuation rates and toleration of this injection-based approach to LDL-C management?

In light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study? Video

In light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study?

Although the AHA Guidelines emphasize CV risk and mortality reductions with statins, ODYSSEY Outcomes provides comparable evidence for alirocumab. How compelling is the evidence for PCSK9 inhibition as a mediator of CV risk and mortality reduction? Video

Although the AHA Guidelines emphasize CV risk and mortality reductions with statins, ODYSSEY Outcomes provides comparable evidence for alirocumab. How compelling is the evidence for PCSK9 inhibition as a mediator of CV risk and mortality reduction?

As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediated CV risk reduction. Where is your specific focus for using these agents in this population? Video

As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediated CV risk reduction. Where is your specific focus for using these agents in this population?